Epigenetic reprogramming of lineage switching in cancer
FEBS Letters · 2026
DOI: 10.1002/1873-3468.70433 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift FEBS Letters, 2026. Verfasst von Ezgi Boyvatlı und 4 weiteren Autor:innen. Beteiligte Einrichtung: Rare and Undiagnosed Diseases Group, İzmir Biomedicine and Genome Center, İzmir, Türkiye. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Neoplasms, Cell Lineage, Cellular Reprogramming. Die Arbeit nennt 178 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Türkiye Bilimsel ve Teknolojik Araştırma Kurumu, Horizon 2020 Framework Programme.
Abstract (Originalsprache)
Lineage plasticity develops as tumor cells overcome terminal differentiation barriers, adapt to environmental stressors, and acquire metastatic, therapy‐resistant phenotypes. These phenotypic transitions are driven by nonmutational epigenetic mechanisms, including dynamic shifts in chromatin accessibility, histone modifications, DNA methylation, and noncoding RNA activity beyond genetic alterations. While epithelial–mesenchymal plasticity (EMP) remains a foundational model, cancer‐cell plasticity extends into a broader pan‐plasticity spectrum encompassing dedifferentiation, transdifferentiation into neuroendocrine or squamous lineages, and stem cell–like reprogramming. In this review, we evaluate how the antagonistic interplay between Polycomb and Trithorax complexes, chromatin modifier activity, and enhancer reprogramming affects lineage identity and enables multi‐lineage plasticity in cancer. We further discuss extrinsic mechanisms reinforced by the tumor microenvironment, particularly hypoxia, chronic inflammation, and metabolic stress, that rewire the epigenetic landscape to stabilize plastic states. Collectively, these data underscore epigenetic deregulation as a primary driver of lineage plasticity and intratumoral heterogeneity, while revealing therapeutic vulnerabilities and the potential to reverse plasticity and overcome therapy resistance by targeting the epigenome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rare and Undiagnosed Diseases Group, İzmir Biomedicine and Genome Center, İzmir, Türkiye.
- Dokuz Eylül University İzmir International Biomedicine and Genome Institute, İzmir, Türkiye.
- Galen Research Center, İzmir Tinaztepe University, İzmir, Türkiye.
- Translational Cancer Research Group, İzmir Biomedicine and Genome Center, İzmir, Türkiye.
- Department of Medical Biology, Faculty of Medicine, İzmir Tinaztepe University, İzmir, Türkiye.
ORCID-Profile: Ezgi Boyvatlı, Burcu Akman, Serap Erkek-Ozhan
Förderung
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
- Horizon 2020 Framework Programme
Zitieren
APA
Boyvatlı, E., Akman, B., Bağırsakçı, E., Atabey, N., & Erkek-Ozhan, S. (2026). Epigenetic reprogramming of lineage switching in cancer. FEBS Letters. https://doi.org/10.1002/1873-3468.70433
Vancouver
Boyvatlı E, Akman B, Bağırsakçı E, Atabey N, Erkek-Ozhan S. Epigenetic reprogramming of lineage switching in cancer. FEBS Letters. 2026. doi:10.1002/1873-3468.70433
BibTeX
@article{Boyvatl2026,
author = {Boyvatlı, Ezgi and Akman, Burcu and Bağırsakçı, Ezgi and Atabey, Nese and Erkek-Ozhan, Serap},
title = {Epigenetic reprogramming of lineage switching in cancer},
journal = {FEBS Letters},
year = {2026},
doi = {10.1002/1873-3468.70433}
}
EUVIMED